Drugs Made In America Acquisition reported total assets of $514.10M and total liabilities of $18.14M for the quarter ended Jun 2026. This balance sheet covers 4 quarters of results from Dec 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Dec2024 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|
| Assets | ||||
| Current Assets | ||||
| Cash & EquivalentsCash & Equiv. | 0.02M | 0.32M | 223.00 | 0.17M |
| Receivables - OtherOther Receivables | 0.57M | |||
| Prepaid Assets | 0.04M | 0.01M | 0.03M | 0.04M |
| Current Assets | 0.06M | 0.90M | 0.03M | 0.22M |
| Non-Current Assets | ||||
| Long-Term Investments | 500.11M | 504.93M | 513.88M | |
| Other Non-Current Assets | 0.08M | |||
| Non-Current Assets | 0.08M | 500.11M | 504.93M | 513.88M |
| Assets | 0.14M | 501.01M | 504.96M | 514.10M |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payables | 0.00M | 0.10M | 0.01M | |
| Notes Payables | 0.25M | 0.45M | ||
| Payables | 0.25M | 0.00M | 0.10M | 0.46M |
| Accumulated Expenses | 0.01M | 0.09M | 0.07M | |
| Other Accumulated Expenses | 0.55M | |||
| Total Current Liabilities | 0.25M | 0.68M | 0.30M | 0.64M |
| Non-Current Liabilities | ||||
| Non-Current Deffered Revenue | 17.50M | 17.50M | 17.50M | |
| Preferred Stock Liabilities | 500.11M | 504.93M | 513.88M | |
| Total Non-Current Liabilities | 17.50M | 17.50M | ||
| Total Liabilities | 0.25M | 18.18M | 17.80M | 18.14M |
| Shareholder's Equity | ||||
| Common Equity | -0.12M | -17.28M | -17.77M | -17.93M |
| Liabilities and Shareholders Equity | 0.14M | 501.01M | 504.96M | 514.10M |
| Retained Earnings | -0.15M | -17.28M | -17.78M | -17.93M |
| Treasury Shares | 50.00M | 50.00M | 50.00M | 50.00M |